Your session is about to expire
← Back to Search
Cognitive Behavioral Therapy + Mindfulness for Alcoholism (ABQTREAT Trial)
N/A
Waitlist Available
Led By Barbara McCrady, PhD
Research Sponsored by University of New Mexico
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 22-85 years
Be older than 18 years old
Must not have
Evidence of current psychosis
History of brain injury or neurological diagnoses
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 4-week within treatment visit, 8-week within treatment visit, and 3-month follow-up, 9-month follow-up, and 15-month follow-up
Awards & highlights
No Placebo-Only Group
Summary
This trial will help researchers understand how changes in brain function relate to someone reducing their alcohol use.
Who is the study for?
This trial is for individuals aged 22-85 who have been drinking alcohol in the past month and score high on an alcohol use assessment. They must be right-handed, seeking help for their drinking, not currently pregnant or using drugs other than marijuana, and without major health issues like psychosis, low IQ, or brain injuries.
What is being tested?
The study tests how Cognitive Behavior Therapy (CBT) and Mindfulness-Based Relapse Prevention (MBRP) affect brain function and behavior in people with Alcohol Use Disorder. Participants will undergo therapy sessions over 12 weeks with assessments before and after treatment to track changes.
What are the potential side effects?
While this trial focuses on psychological treatments rather than medication, participants may experience emotional discomfort as they confront their alcohol use patterns during therapy sessions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 22 and 85 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently experiencing psychosis.
Select...
I have had a brain injury or been diagnosed with a neurological condition.
Select...
I cannot read or speak English fluently.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 4-week within treatment visit, 8-week within treatment visit, and 3-month follow-up, 9-month follow-up, and 15-month follow-up
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 4-week within treatment visit, 8-week within treatment visit, and 3-month follow-up, 9-month follow-up, and 15-month follow-up
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
MOBC: Cognitive and Behavioral Control - behavior
MOBC: Cognitive and Behavioral Control - neuroimaging errors
MOBC: Cognitive and Behavioral Control - neuroimaging inhibition
+5 moreSecondary study objectives
Drinks per drinking day
Percent drinking days
Percent heavy drinking days
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Cognitive-Behavior TherapyActive Control1 Intervention
The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein \& McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
Group II: Mindfulness Based Relapse PreventionActive Control1 Intervention
The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz \& Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
Find a Location
Who is running the clinical trial?
University of New MexicoLead Sponsor
388 Previous Clinical Trials
3,526,493 Total Patients Enrolled
17 Trials studying Alcoholism
3,009 Patients Enrolled for Alcoholism
The Mind Research NetworkOTHER
26 Previous Clinical Trials
2,232 Total Patients Enrolled
8 Trials studying Alcoholism
926 Patients Enrolled for Alcoholism
Barbara McCrady, PhDPrincipal InvestigatorThe University of New Mexico
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a history of severe alcohol withdrawal symptoms.I am not pregnant, as confirmed by a urine test before each MRI scan.You have had a problem with drugs or alcohol (excluding cigarettes or marijuana) within the past year.You have consumed alcohol within the past month.I am between 22 and 85 years old.You are actively looking for help to address your drinking problem.I am currently experiencing psychosis.I have had a brain injury or been diagnosed with a neurological condition.Your estimated intelligence quotient (IQ) is below 80.I cannot read or speak English fluently.You regularly drink a lot of alcohol or have episodes of excessive drinking.
Research Study Groups:
This trial has the following groups:- Group 1: Cognitive-Behavior Therapy
- Group 2: Mindfulness Based Relapse Prevention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.